title: Stereotactic body radiation therapy for treatment of primary and metastatic pulmonary malignancies.
abstract: Stereotactic body radiation therapy (SBRT) has become the preferred treatment approach for patients with stage I non-small cell lung cancer who are medically inoperable or refuse surgery. SBRT consists of 3 to 5 radiation treatments delivered over a 10- to 14-day period. Local control is achieved in approximately 90% of patients, and the risk of toxicity is relatively low. Ongoing studies are examining whether SBRT can replace surgery for certain patients, the optimal dose-fractionation scheme, and how best to treat patients having central tumors near the primary tracheobronchial tree.
authors.affiliation: Department of Radiation Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA. christopher.kelsey@dm.duke.edu
authors.forename: Chris R
authors.initials: CR
authors.lastname: Kelsey
authors.forename: Joseph K
authors.initials: JK
authors.lastname: Salama
mesh_terms: D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary* / Q000601:surgery*; D011379:Prognosis; D016634:Radiosurgery